Urine drug testing uses two complementary approaches: immunoassay (IA) for fast, presumptive, class-level screening, and mass spectrometry (GC-MS or LC-MS/MS) for definitive, specific, quantitative confirmation. Understanding where each fails is central to interpreting a result correctly.¹

Immunoassay cutoffs were designed to detect illicit use and are higher than mass spectrometry, so IA can miss medications at therapeutic doses; one analysis of 218,927 specimens found clinical false-negative rates versus definitive testing of about 34% for benzodiazepines and 41% for THC.² IA also produces false positives from cross-reacting compounds.³

Choose the method by the clinical goal. Immunoassay suits rapid, time-critical screening but is class-level and error-prone. LC-MS/MS identifies specific drugs and metabolites at low concentrations with high sensitivity and specificity, and is largely replacing GC-MS because it needs less sample, runs faster, and detects 50 or more analytes at once.¹ The cocaine immunoassay is notably accurate, while the PCP assay is not.³

• Interpret every immunoassay result as presumptive; confirm before acting.¹
• Confirm positives, and clinically important negatives, with LC-MS/MS.²
• Know the common false positives: ibuprofen to THC; bupropion, pseudoephedrine, trazodone to amphetamines; dextromethorphan, venlafaxine to PCP; quetiapine to methadone.³
• Know the common false negatives: fentanyl on opiate screens; clonazepam and lorazepam on benzodiazepine screens.³
• Do not rely on semiquantitative immunoassay values; they correlate poorly with true concentrations.